1
Patients’ Satisfaction with Breakthrough Cancer Pain Therapy: A Secondary Analysis of IOPS-MS Study

von Mazzotta M ; Filetti M ; Piras M ; et al.

Cancer Management and Research, Vol 14, Pp 1237-1245 (2022)

Schlagworte: breakthrough cancer pain; opioids; pain control; patient satisfaction; quality of life.; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282
- Zum Volltext in DOAJ
Merkliste

2
Impact of ECOG performance status 2 participants on outcomes of pivotal cancer clinical trials: a meta-analysis and meta-regression

von Iannantuono, G.M. ; Giovagnoli, T. ; Mastrantoni, L. ; et al.

In ESMO Open February 2026 11(2)
- View full text via DOI
Merkliste

3
Integration of translational research in phase III trials: A systematic review of breast cancer studies in a 5-year period

von Giannone, G. ; Lombardi, P. ; Filetti, M. ; et al.

In The Breast June 2025 81
- View full text via DOI
Merkliste

4
Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO)

von Pizzutilo, E.G. ; Agostara, A.G. ; Oresti, S. ; et al.

In ESMO Open June 2024 9(6)
- View full text via DOI
Merkliste

5
Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort study

von Fletcher K. ; Cortellini A. ; Ganta T. ; et al.

Schlagworte: Anti-PD-1 therapy; Geriatric population; Immune-related adverse event; Immunotherapy; Melanoma
- View full text via BASE
Merkliste

6
Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario

von Cantini, L. ; Mentrasti, G. ; Russo, G.L. ; et al.

In ESMO Open April 2022 7(2)
- View full text via DOI
Merkliste

7
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer

von Banna, G.L. ; Cortellini, A. ; Cortinovis, D.L. ; et al.

In ESMO Open April 2021 6(2)
- View full text via DOI
Merkliste

8
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study

von Cantini L. ; Paoloni F. ; Pecci F. ; et al.
- View full text via BASE
Merkliste

9
La medicina di precisione come opera d’arte collettiva

von Filetti M. ; Petti M. ; Farina L. ; et al.

Schlagworte: medicina di precisione; intelligenza artificiale; analisi dei big data
- View full text via BASE
Merkliste

10
KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden

von Marinelli, D. ; Mazzotta, M. ; Scalera, S. ; et al.

In Annals of Oncology December 2020 31(12):1746-1754
- View full text via DOI
Merkliste

11
Characterization of Age-Associated, Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammatory Index (SII) as Biomarkers of Inflammation in Geriatric Patients with Cancer Treated with Immune Checkpoint Inhibitors: Impact on Efficacy and Survival

von Choucair K. ; Nebhan C. ; Cortellini A. ; et al.

Schlagworte: biomarker; circulating inflammatory marker; geriatric oncology; immune checkpoint inhibitor; systemic immune-inflammatory index
- View full text via BASE
Merkliste

12
1585P Performance status restrictions in clinical trials leading to US food and drug administration (FDA) drug approval: A cross-sectional study of a decade (2014-2023)

von Iannantuono, G.M. ; Filetti, M. ; Giudice, E. ; et al.

Annals of Oncology ; volume 35, page S956-S957 ; ISSN 0923-7534
- View full text via BASE
Merkliste

13
1338P TP53 truncating and missense mutations are linked to differential response to checkpoint blockade in patients with advanced non-small cell lung cancer (NSCLC)

von Citarella, F. ; Russano, M. ; Fiorenti, M. ; et al.

Annals of Oncology ; volume 35, page S848 ; ISSN 0923-7534
- View full text via BASE
Merkliste

14
SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry

von Cortellini A. ; Tabernero J. ; Mukherjee U. ; et al.

Schlagworte: COVID-19; COVID-19 Testing; Disease Progression; Female; Human; Male; Neoplasm; SARS-CoV-2
- View full text via BASE
Merkliste

15
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status

von Cortellini A. ; Giusti R. ; Filetti M. ; et al.

Schlagworte: ddr gene; family history of cancer; immune checkpoint inhibitor; immunotherapy; nsclc; pembrolizumab; carcinoma; non-small-cell lung; dna damage; female; human; lung neoplasm; male; treatment outcome
- View full text via BASE
Merkliste

16
New driver alterations in non-small cell lung cancer. A narrative review

von Filetti M. ; Rossi A. ; Salimbeni B. T. ; et al.

Schlagworte: driver mutation; precision oncology; non-small cell lung cancer (nsclc)
- View full text via BASE
Merkliste

17
INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A multicenter prospective observational study (INVIDIa-2)

von Bersanelli M. ; Giannarelli D. ; De Giorgi U. ; et al.

Schlagworte: antibodies; immunization; immunogenicity; immunotherapy; neoplasm; vaccination; vaccine; Adult; Aged; 80 and over; Female; Humans; Immune Checkpoint Inhibitors; Incidence; Influenza Vaccines; Influenza; Human; Italy; Male; Middle Aged; Neoplasms; Prospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Young Adult; Vaccine Efficacy
- View full text via BASE
Merkliste

18
Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer

von Pinato, DJ ; Ferrante, D ; Aguilar-Company, J ; et al.

Schlagworte: COVID-19; SARS-CoV-2; Vaccine; Prevention; Cancer; Clinical efficacy
- View full text via BASE
Merkliste

19
Erratum to ‘Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario’: [ESMO Open Volume 7, Issue 2, April 2022, 100406]

von Cantini, L. ; Mentrasti, G. ; Lo Russo, G. ; et al.

Schlagworte: lung cancer; COVID-19; diagnostic delay; therapeutic delay; staging
- View full text via BASE
Merkliste

20
Efficacy and safety of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: A systematic review and network meta-analysis

von Filetti M. ; Lombardi P. ; Giusti R. ; et al.

Schlagworte: Anti-emetic drug; Chemotherapy-induced nausea and vomiting; Emesi; NK-1 receptor antagonist; Olanzapine; Settore MEDS-24/A - Statistica medica
- View full text via BASE
Merkliste

21
Comparing efficacy and safety of upfront treatment strategies for anaplastic lymphoma kinase-positive non-small cell lung cancer: a network meta-analysis

von Filetti M. ; Lombardi P. ; Falcone R. ; et al.

Schlagworte: anaplastic lymphoma kinase translocation; Non-small cell lung cancer; targeted therapy; Settore MEDS-24/A - Statistica medica
- View full text via BASE
Merkliste

22
Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer

von Cortellini, A ; D'Alessio, A ; Cleary, S ; et al.

Clinical Cancer Research , 29 (14) pp. 2714-2724. (2023)

Schlagworte: Humans; Carcinoma; Non-Small-Cell Lung; Immune Checkpoint Inhibitors; Diabetes Mellitus; Type 2; Lung Neoplasms; Metformin; Disease Progression; Retrospective Studies; Tumor Microenvironment
- View full text via BASE
Merkliste

23
Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study

von Pinato D. J. ; Tabernero J. ; Bower M. ; et al.

Schlagworte: COVID-19; OnCovid; cancer treatment
- View full text via BASE
Merkliste

24
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes

von Cortellini, A. ; Leonetti, A. ; Catino, A. ; et al.

Clinical and Translational Oncology. 22(6):844-851
- Zum Volltext (via ReDI)
Merkliste

25
Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy

von Buti S. ; Bersanelli M. ; Perrone F. ; et al.

Schlagworte: Concomitant medication; First-line; Immunotherapy; Non–small-cell lung cancer; Pembrolizumab; Predictive score
- View full text via BASE
Merkliste

12 3 4 5 6 7 8 9 10 11 weiter »

Sie haben nicht gefunden, wonach Sie gesucht haben? Diese Services können Ihnen weiterhelfen.
Hilfe & Kontakt ǀ Fernleihe | Hilfe zur Fernleihe ǀ Literaturvorschlag| Literaturvorschlag